Compile Data Set for Download or QSAR
Found 1314 with Last Name = 'randl' and Initial = 'sa'
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251408(US9452990, 90)copy SMILEScopy InChI
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM50400274(CHEMBL2180765 | US9085555, 373)copy SMILEScopy InChI
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251420(US9452990, 102)copy SMILEScopy InChI
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM50400273(CHEMBL2180764 | US9085555, 375)copy SMILEScopy InChI
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254483(US9468661, 61)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170738(US9085555, 166)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254498(US9468661, 109 | US9468661, 76)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251413(US9452990, 95)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251449(US9452990, 131)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171305(US9085555, 735)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171311(US9085555, 741 | US9085555, 757)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171262(US9085555, 692)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171267(US9085555, 697)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170864(US9085555, 292)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170890(US9085555, 318)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170943(US9085555, 371)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170945(US9085555, 374)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM50400275(CHEMBL2180766 | US9085555, 127)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254486(US9468661, 64)copy SMILES
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251397(US9452990, 77)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251411(US9452990, 93)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254471(US9468661, 49)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254475(US9468661, 53)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254488(US9468661, 66)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171304(US9085555, 734)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170701(US9085555, 129)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171318(US9085555, 748)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171319(US9085555, 749)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171334(US9085555, 764)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170872(US9085555, 300)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170878(US9085555, 306)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170953(US9085555, 383)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171314(US9085555, 744)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254528(US9468661, 106)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251348(US9452990, 28)copy SMILES
Affinity DataIC50: 5nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171311(US9085555, 741 | US9085555, 757)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171313(US9085555, 743)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171315(US9085555, 745)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171324(US9085555, 754)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170734(US9085555, 162)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171208(US9085555, 638)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171255(US9085555, 685)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170866(US9085555, 294)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170934(US9085555, 362)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170949(US9085555, 379)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM171332(US9085555, 762)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetCobra venom factor/Complement factor B/Complement factor D(Naja kaouthia (Monocled cobra) (Naja siamensis))
NOVARTIS AG

US Patent
LigandPNGBDBM251451(US9452990, 80)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2H130Z9US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM170775(US9085555, 203)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2RN36MPUS Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM256239(US9487483, 91)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2R78D53US Patent
TargetComplement factor D(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM254454(US9468661, 32)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q23N22B5US Patent
Displayed 1 to 50 (of 1314 total ) | Next | Last >>
Jump to: